Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 - Marc Bourlière, Stuart C. Gordon, Eugene R. Schiff, Tram T. Tran, Natarajan Ravendhran, Charles S. Landis, Robert H. Hyland, Luisa M. Stamm, Jie Zhang, Hadas Dvory-Sobol, G. Mani Subramanian, Diana M. Brainard, John G. McHutchison, Lawrence Serfaty, Alex J. Thompson - Dissemin

Language
Login

Published in

Elsevier, Lancet Gastroenterology and Hepatology, 8(3), p. 559-565

DOI: 10.1016/s2468-1253(18)30118-3

Links

Elsevier

Tools

Export citation

Search in Google Scholar

Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

Journal article published in 2018 by Marc Bourlière, Stuart C. Gordon, Eugene R. Schiff, Tram T. Tran, Natarajan Ravendhran, Charles S. Landis, Robert H. Hyland, Luisa M. Stamm, Jie Zhang, Hadas Dvory-Sobol, G. Mani Subramanian, Diana M. Brainard, John G. McHutchison, Lawrence Serfaty, Alex J. Thompson and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO

Beta version